Morning Overview on MSN
Capivasertib won FDA approval for a hard-to-treat form of prostate cancer
Men diagnosed with metastatic prostate cancer that lacks the PTEN protein now have a targeted drug option for the first time.
Objectives Elective non-emergent surgical wait times have increased across countries such as Canada, straining operating room ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results